Detalhe da pesquisa
1.
Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer.
BMC Cancer
; 22(1): 526, 2022 May 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35545761
2.
Ribosome biogenesis-based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTORIA trial in collaboration with the GINECO group.
Mol Oncol
; 17(1): 27-36, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36370117